Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT06899932
Recruiting Observational

Survival Study of the Genutech® Total Knee Arthroplasty

NCT06899932 · tracked via the Priya Life Science Spain tracker
Sponsor
Hospital de Sant Rafael
Phase
Observational
Started
2021-01-01
Last updated
2025-03-28

Condition(s) studied

Knee Osteoarthritis

Study summary

Prospective cohort sudy of patients undergoing a Genutech® total knee arthroplasty

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients older than 18 years with knee osteoarthritis that had not responded to conservative treatment * capable of providing informed consent * patients who receive a Genutech® total knee prosthesis at the investigators' Institution. Exclusion Criteria: * having received a prior total knee arthroplasty in the same joint * inability to provide informed consent * not willing to participate in the study

Primary outcome measure(s)

  • Number of patients without revision surgery — 5 and 10 years
    the main goal is to determine the implant survival, that is, having no revision during follow-up. The number of patients requiring revision will be compared to the total of patients included in the study.

Trial sites (1)

FacilityCityRegionStatus
Hospital Sant Rafael Barcelona Barcelona Recruiting

Other trials for the same condition

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis Active, not recruiting
Multicenter Clinical Trial Comparing Treatment with Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control with Hyaluronic Acid in Patients with Knee Osteoarthritis. Active, not recruiting
Effectiveness of a Prehabilitation Program for Hip or Knee Arthroplasty Surgery. Active, not recruiting
Efficacy of Artificial Intelligence-Assisted Therapeutic Exercise in Patients With Knee Osteoarthritis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06899932 on ClinicalTrials.gov ↗ ← All trials in Spain